<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25487708</article-id><article-id pub-id-type="pmc">4289171</article-id><article-id pub-id-type="publisher-id">5083</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-897</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Gibbs</surname><given-names>Peter</given-names></name><address><email>peter.gibbs@mh.org.au</email></address><xref ref-type="aff" rid="Aff11"/><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Gebski</surname><given-names>Val</given-names></name><address><email>val.gebski@sydney.edu.au</email></address><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Van Buskirk</surname><given-names>Mark</given-names></name><address><email>mark@datareduction.net</email></address><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Thurston</surname><given-names>Kenneth</given-names></name><address><email>kthurston@sirtex.com</email></address><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Cade</surname><given-names>David N</given-names></name><address><email>dcade@sirtex.com</email></address><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Van Hazel</surname><given-names>Guy A</given-names></name><address><email>gvh@perthoncology.com.au</email></address><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><collab>SIRFLOX Study Group</collab></contrib><aff id="Aff11"><label/>Royal Melbourne Hospital, Melbourne, Victoria Australia </aff><aff id="Aff12"><label/>NHMRC Clinical Trials Centre, Camperdown, New South Wales Australia </aff><aff id="Aff13"><label/>Data Reduction LLC, Chester, New Jersey USA </aff><aff id="Aff14"><label/>Sirtex Medical Limited, North Sydney, New South Wales Australia </aff><aff id="Aff15"><label/>University of Western Australia, Perth, Western Australia Australia </aff><aff id="Aff16"><label/>Walter and Eliza Hall Institute Medical Research, Melbourne, Australia </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>897</elocation-id><history><date date-type="received"><day>24</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Gibbs et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>In colorectal cancer (CRC), unresectable liver metastases are linked to poor prognosis. Systemic chemotherapy with regimens such as FOLFOX (combination of infusional 5-fluorouracil, leucovorin and oxaliplatin) is the standard first-line treatment. The SIRFLOX trial was designed to assess the efficacy and safety of combining FOLFOX-based chemotherapy with Selective Internal Radiation Therapy (SIRT or radioembolisation) using yttrium-90 resin microspheres (SIR-Spheres&#x000ae;; Sirtex Medical Limited, North Sydney, Australia).</p></sec><sec><title>Methods/Design</title><p>SIRFLOX is a randomised, multicentre trial of mFOLFOX6 chemotherapy&#x02009;&#x000b1;&#x02009;SIRT as first-line treatment of patients with liver-only or liver-predominant metastatic CRC (mCRC). The trial aims to recruit adult chemotherapy-na&#x000ef;ve patients with proven liver metastases with or without limited extra-hepatic disease, a life expectancy of &#x02265;3&#x000a0;months and a WHO performance status of 0&#x02013;1. Patients will be randomised to receive either mFOLFOX6 or SIRT&#x02009;+&#x02009;mFOLFOX6 (with a reduced dose of oxaliplatin in cycles 1&#x02013;3 following SIRT). Patients in both arms can receive bevacizumab at investigator discretion. Protocol chemotherapy will continue until there is unacceptable toxicity, evidence of tumour progression, complete surgical resection or ablation of cancerous lesions, or the patient requests an end to treatment. The primary endpoint of the SIRFLOX trial is progression-free survival (PFS). Secondary endpoints include: PFS in the liver; tumour response rate (liver and any site); site of tumour progression; health-related quality of life; toxicity and safety; liver resection rate; and overall survival. Assuming an increase in the median PFS from 9.4&#x000a0;months to 12.5&#x000a0;months with the addition of SIRT to mFOLFOX6, recruiting &#x02265;450 patients will be sufficient for 80% power and 95% confidence.</p></sec><sec><title>Discussion</title><p>The SIRFLOX trial will establish the potential role of SIRT&#x02009;+&#x02009;standard systemic chemotherapy in the first-line management of mCRC with non-resectable liver metastases.</p></sec><sec><title>Trial registration</title><p>SIRFLOX ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00724503">NCT00724503</ext-link>. Registered 25 July 2008.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/1471-2407-14-897) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Metastatic colorectal cancer</kwd><kwd>Liver metastases</kwd><kwd>Systemic chemotherapy</kwd><kwd>SIR-Spheres&#x000ae; microspheres</kwd><kwd>Selective Internal Radiation Therapy (SIRT)</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>In colorectal cancer (CRC), liver metastases are linked to poor prognosis &#x02013; death and recurrence are frequently attributable to liver metastases [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Surgical resection of CRC liver metastases can result in cure, and produces 5-year survival of 27-39% and 10-year survival of 12-36% [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], as opposed to median survival of approximately 9&#x000a0;months if untreated [<xref ref-type="bibr" rid="CR6">6</xref>]. However, only 10-20% of patients with liver metastases from CRC are candidates for such surgery [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>], and intra-hepatic and extra-hepatic relapse after liver resection is common [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Systemic chemotherapy is, therefore, used as first-line treatment in patients with non-resectable liver metastases [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>], and in some cases can sufficiently down-size the tumour burden in patients with previously inoperable liver metastases so that they may be converted to candidates for potentially curative resection [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Internationally accepted first-line chemotherapy regimens for patients with mCRC include FOLFOX (combination of bolus and infusional 5-fluorouracil [5-FU], leucovorin [LV] and oxaliplatin) and FOLFIRI (combination of bolus and infusional 5-FU, LV and irinotecan). These regimens provide median survival times of 16&#x02013;20 months [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR20">20</xref>], and the addition of biologic agents, such as bevacizumab and cetuximab, to chemotherapy regimens may enhance progression-free survival (PFS) and overall survival (OS) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Selective Internal Radiation Therapy (SIRT or radioembolisation) is an innovative radiation therapy for mCRC, which involves the delivery of SIR-Spheres&#x000ae; (Sirtex Medical Limited, North Sydney, Australia), that contain the &#x003b2;-emitter yttrium-90, into the arterial supply of the liver. These resin microspheres are delivered via a trans-femoral hepatic artery catheter. In a randomised Phase II trial, treatment of mCRC with SIRT plus first-line 5-FU/LV chemotherapy resulted in a longer time-to-progression (18.6&#x000a0;months) compared with 5-FU/LV chemotherapy alone (3.6&#x000a0;months) [<xref ref-type="bibr" rid="CR22">22</xref>]. A subsequent Phase I clinical trial demonstrated that SIRT combined with FOLFOX4 systemic chemotherapy had acceptable tolerability [<xref ref-type="bibr" rid="CR23">23</xref>]. In this trial of 20 patients with non-resectable liver metastases from CRC, SIRT was administered on the third or fourth day of the first cycle of first-line chemotherapy. The dose-limiting toxicity was grade 3/4 neutropenia, and the authors suggested the maximum tolerated dose of oxaliplatin was 60&#x000a0;mg/m<sup>2</sup> for the first three cycles, with full-dose FOLFOX4 thereafter [<xref ref-type="bibr" rid="CR23">23</xref>]. Although the primary endpoint of this study was toxicity, the objective response rate according to Response Evaluation Criteria In Solid Tumours (RECIST) was 90%, two patients (10%) were down-staged to undergo hepatic resection and median PFS was 9.3&#x000a0;months [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>These results suggest that the combination of SIRT and FOLFOX systemic chemotherapy warrants further investigation. Consequently, two open-label, randomised, controlled Phase III trials of mFOLFOX6&#x02009;&#x000b1;&#x02009;SIRT as first-line treatment of patients with liver-only or liver-predominant mCRC were designed with virtually identical protocols (SIRFLOX and FOXFIRE). The primary endpoint of SIRFLOX is a comparison between treatment arms of PFS.</p></sec><sec id="Sec2"><title>Methods/Design</title><p>The SIRFLOX study will be conducted in accordance with the Declaration of Helsinki, and approval has been obtained from the relevant ethics committees for each participating centre (see Additional file <xref rid="MOESM1" ref-type="media">1</xref> for a list). When the results of the study are reported, CONSORT guidelines will be adhered to.</p><sec id="Sec3"><title>Eligible population</title><p>The inclusion and exclusion criteria for the SIRFLOX study is summarised in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Patient eligibility criteria for SIRFLOX study</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inclusion criteria</th><th>Exclusion criteria</th></tr></thead><tbody><tr><td>&#x025cf; Written informed consent provided.</td><td>&#x025cf; Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour involvement or main portal venous thrombosis.</td></tr><tr><td>&#x025cf; Aged &#x02265;18&#x000a0;years with histologically confirmed adenocarcinoma of the colon or rectum (with or without the primary tumour <italic>in situ</italic>).</td><td>&#x025cf; Previous radiation therapy to the upper abdomen.</td></tr><tr><td>&#x025cf; Proven liver metastases.</td><td>&#x025cf; Non-malignant disease that renders patients unsuitable for the study treatment.</td></tr><tr><td>&#x025cf; WHO performance status of 0&#x02013;1.</td><td>&#x025cf; Grade &#x0003e;1 peripheral neuropathy (NCI-CTCv3).</td></tr><tr><td>&#x025cf; Life expectancy of &#x02265;3&#x000a0;months.</td><td>&#x025cf; Previous dose-limiting toxicity associated with adjuvant 5-FU or oxaliplatin chemotherapy.</td></tr><tr><td>&#x025cf; Patients with additional limited extra-hepatic metastases in the lung or lymph nodes (fewer than 5 nodules &#x02264;1&#x000a0;cm diameter or a single nodule &#x02264;1.7&#x000a0;cm diameter in the lung, and lymph node involvement in a single anatomical area &#x0003c;2&#x000a0;cm diameter) with the aim of these patients being &#x0003c;40% of the total number of patients recruited (but not being excluded even if they account for more than this proportion).</td><td>&#x025cf; Pregnancy or breast-feeding.</td></tr><tr><td>&#x025cf; Chemotherapy-na&#x000ef;ve for mCRC, but previous adjuvant systemic chemotherapy for primary CRC or neoadjuvant chemo-radiotherapy to the pelvis more than 6&#x000a0;months before recruitment are permitted.</td><td>&#x025cf; Current or history of cancer other than adequately treated non-melanoma skin cancer or carcinoma <italic>in situ</italic> of the cervix.</td></tr><tr><td>&#x025cf; Deemed suitable for either treatment regimen by the investigator.</td><td>&#x025cf; Allergy to non-ionic contrast agents.</td></tr><tr><td>&#x025cf; Adequate haematological, renal and hepatic function.</td><td/></tr><tr><td>&#x025cf; Using an acceptable method of contraception.</td><td/></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Overview of study design</title><p>SIRFLOX is a randomised, multicentre study of mFOLFOX6&#x02009;&#x000b1;&#x02009;SIRT as first-line treatment of patients with inoperable liver-only or liver-predominant mCRC. In SIRFLOX, the aim will be to recruit a minimum of 450 patients at a minimum of 35 sites in Australia, Europe, Israel, New Zealand and USA. Eligible patients are randomised 1:1 to receive either systemic chemotherapy with 5-FU/LV&#x02009;+&#x02009;oxaliplatin (FOLFOX; control arm) or single-session whole liver SIRT&#x02009;+&#x02009;systemic chemotherapy with 5-FU/LV&#x02009;+&#x02009;oxaliplatin (FOLFOX; intervention arm) (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). All patients may also receive bevacizumab at the investigator&#x02019;s discretion.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Overview of SIRFLOX study design.</bold> Figure footnote: * Bevacizumab, at the investigator&#x02019;s discretion, but not until cycle 4.</p></caption><graphic xlink:href="12885_2014_5083_Fig1_HTML" id="d30e584"/></fig></p></sec><sec id="Sec5"><title>Randomisation and stratification</title><p>When a patient is eligible to participate in the study, randomisation, using the method of minimisation, will be performed using a centralised Study Randomisation Centre at the NHMRC Clinical Trial Centre at the University of Sydney. Treatment will be allocated randomly using the following stratification parameters: liver-only versus extra-hepatic metastases (at least 60% of recruited patients will have liver-only metastases); the extent of tumour involvement of the liver (classed as &#x02264;25% or &#x0003e;25% tumour involvement determined by CT scan, and based upon the tumour involvement groupings used by Gray et al. [<xref ref-type="bibr" rid="CR24">24</xref>]); planned use of bevacizumab with chemotherapy; and investigational centre.</p></sec><sec id="Sec6"><title>Protocol treatment</title><p>Systemic chemotherapy must start within 28&#x000a0;days of randomisation. Treatment cycles are described in Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. All patients will be monitored until death or for a minimum of 5&#x000a0;years. Patients randomised to the intervention arm will require a hepatic angiogram and a liver-to-lung shunt study before the SIRT procedure to determine their suitability to receive this treatment. The prescribed activity of SIR-Spheres will be determined from the patient&#x02019;s body surface area (BSA), the percentage tumour involvement, and the magnitude of liver-to-lung shunting (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Treatment received as part of the SIRFLOX study.</bold> Figure footnote: <sup>&#x02021;</sup>Bevacizumab can be added at the investigator&#x02019;s discretion starting at cycle 1 (or according to the institutional protocol). <sup>&#x02020;</sup>Bevacizumab can be added at the investigator&#x02019;s discretion but should not be initiated until cycle 4 (or according to the institutional protocol). If leucovorin is not available, levofolinic acid can be used at a dose of 100&#x000a0;mg/m<sup>2</sup>. If a centre considers leucovorin 400&#x000a0;mg/m<sup>2</sup> the standard dose, then this will be allowed at the investigator&#x02019;s discretion. LV&#x02009;=&#x02009;Leucovorin; 5-FU =5-Fluorouracil.</p></caption><graphic xlink:href="12885_2014_5083_Fig2_HTML" id="d30e627"/></fig></p><table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Administered dose calculator used in the SIRFLOX study</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="16">Percentage tumour involvement</th></tr><tr><th>BSA</th><th>0-5</th><th>6-10</th><th>11-15</th><th>16-20</th><th>21-25</th><th>26-30</th><th>31-35</th><th>36-40</th><th>41-45</th><th>46-50</th><th>51-55</th><th>56-60</th><th>61-65</th><th>66-70</th><th>71-75</th><th>76-80</th></tr></thead><tbody><tr><td align="center"/><td align="center" colspan="16">
<bold>0-10% lung breakthrough</bold>
</td></tr><tr><td>1.30-1.35</td><td align="center">0.7</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.1</td><td align="center">1.1</td></tr><tr><td>1.36-1.40</td><td align="center">0.7</td><td align="center">0.9</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.2</td><td align="center">1.1</td></tr><tr><td>1.41-1.45</td><td align="center">0.7</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.2</td></tr><tr><td>1.46-1.50</td><td align="center">0.8</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td><td align="center">1.2</td></tr><tr><td>1.51-1.55</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td></tr><tr><td>1.56-1.60</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td></tr><tr><td>1.61-1.65</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td></tr><tr><td>1.66-1.70</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.4</td></tr><tr><td>1.71-1.75</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td></tr><tr><td>1.76-1.80</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td></tr><tr><td>1.81-1.85</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>1.86-1.90</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.1</td><td align="center">2.1</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td></tr><tr><td>1.91-1.95</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.1</td><td align="center">2.1</td><td align="center">2.1</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.6</td></tr><tr><td>1.96-2.00</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.1</td><td align="center">2.2</td><td align="center">2.2</td><td align="center">2.2</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td></tr><tr><td>2.01-2.05</td><td align="center">1.0</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.1</td><td align="center">2.2</td><td align="center">2.3</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td></tr><tr><td>2.06-2.10</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.2</td><td align="center">2.3</td><td align="center">2.3</td><td align="center">2.3</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td></tr><tr><td>2.11-2.15</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.2</td><td align="center">2.3</td><td align="center">2.4</td><td align="center">2.4</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td></tr><tr><td>2.16-2.20</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.9</td><td align="center">2.1</td><td align="center">2.3</td><td align="center">2.4</td><td align="center">2.4</td><td align="center">2.4</td><td align="center">2.4</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.8</td></tr><tr><td>2.21-2.25</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.1</td><td align="center">2.3</td><td align="center">2.4</td><td align="center">2.5</td><td align="center">2.5</td><td align="center">2.4</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td></tr><tr><td>2.26-2.30</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.7</td><td align="center">2.0</td><td align="center">2.2</td><td align="center">2.4</td><td align="center">2.5</td><td align="center">2.5</td><td align="center">2.5</td><td align="center">2.5</td><td align="center">2.4</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td></tr><tr><td>2.31-2.35</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">2.0</td><td align="center">2.2</td><td align="center">2.4</td><td align="center">2.5</td><td align="center">2.6</td><td align="center">2.6</td><td align="center">2.5</td><td align="center">2.5</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td></tr><tr><td>2.36-2.40</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.3</td><td align="center">2.5</td><td align="center">2.6</td><td align="center">2.6</td><td align="center">2.6</td><td align="center">2.6</td><td align="center">2.5</td><td align="center">2.4</td><td align="center">2.3</td><td align="center">2.1</td><td align="center">2.0</td><td align="center">1.9</td></tr><tr><td>2.41-2.45</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.8</td><td align="center">2.1</td><td align="center">2.3</td><td align="center">2.5</td><td align="center">2.6</td><td align="center">2.7</td><td align="center">2.7</td><td align="center">2.6</td><td align="center">2.6</td><td align="center">2.4</td><td align="center">2.3</td><td align="center">2.2</td><td align="center">2.0</td><td align="center">1.9</td></tr><tr><td>2.46-2.50</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.8</td><td align="center">2.1</td><td align="center">2.4</td><td align="center">2.6</td><td align="center">2.7</td><td align="center">2.8</td><td align="center">2.8</td><td align="center">2.7</td><td align="center">2.6</td><td align="center">2.5</td><td align="center">2.4</td><td align="center">2.2</td><td align="center">2.1</td><td align="center">2.0</td></tr><tr><td align="center"/><td align="center" colspan="16">
<bold>11-15% lung breakthrough</bold>
</td></tr><tr><td>1.30-1.35</td><td align="center">0.7</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.1</td><td align="center">1.1</td></tr><tr><td>1.36-1.40</td><td align="center">0.7</td><td align="center">0.9</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.2</td><td align="center">1.1</td></tr><tr><td>1.41-1.45</td><td align="center">0.7</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.2</td></tr><tr><td>1.46-1.50</td><td align="center">0.8</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td><td align="center">1.2</td></tr><tr><td>1.51-1.55</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td></tr><tr><td>1.56-1.60</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td></tr><tr><td>1.61-1.65</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td></tr><tr><td>1.66-1.70</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.4</td></tr><tr><td>1.71-1.75</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td></tr><tr><td>1.76-1.80</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.4</td></tr><tr><td>1.81-1.85</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>1.86-1.90</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.5</td></tr><tr><td>1.91-1.95</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td><td align="center">1.6</td></tr><tr><td>1.96-2.00</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td></tr><tr><td>2.01-2.05</td><td align="center">1.0</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td><td align="center">1.6</td></tr><tr><td>2.06-2.10</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td></tr><tr><td>2.11-2.15</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.6</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.7</td></tr><tr><td>2.16-2.20</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.6</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td><td align="center">1.8</td></tr><tr><td>2.21-2.25</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.7</td><td align="center">1.9</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td></tr><tr><td>2.26-2.30</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.7</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td><td align="center">1.8</td></tr><tr><td>2.31-2.35</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.7</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td></tr><tr><td>2.36-2.40</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td></tr><tr><td>2.41-2.45</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">1.9</td></tr><tr><td>2.46-2.50</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.8</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td><td align="center">2.0</td></tr><tr><td align="center"/><td align="center" colspan="16">
<bold>16-20% lung breakthrough</bold>
</td></tr><tr><td>1.30-1.35</td><td align="center">0.7</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.1</td><td align="center">1.1</td></tr><tr><td>1.36-1.40</td><td align="center">0.7</td><td align="center">0.9</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.2</td><td align="center">1.1</td></tr><tr><td>1.41-1.45</td><td align="center">0.7</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td><td align="center">1.2</td></tr><tr><td>1.46-1.50</td><td align="center">0.8</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td><td align="center">1.2</td></tr><tr><td>1.51-1.55</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.2</td></tr><tr><td>1.56-1.60</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td><td align="center">1.3</td></tr><tr><td>1.61-1.65</td><td align="center">0.8</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.3</td></tr><tr><td>1.66-1.70</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td><td align="center">1.4</td></tr><tr><td>1.71-1.75</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td></tr><tr><td>1.76-1.80</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.4</td></tr><tr><td>1.81-1.85</td><td align="center">0.9</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>1.86-1.90</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>1.91-1.95</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>1.96-2.00</td><td align="center">1.0</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.01-2.05</td><td align="center">1.0</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.06-2.10</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.11-2.15</td><td align="center">1.1</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.16-2.20</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.21-2.25</td><td align="center">1.1</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.26-2.30</td><td align="center">1.2</td><td align="center">1.4</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.31-2.35</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.36-2.40</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.41-2.45</td><td align="center">1.2</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr><tr><td>2.46-2.50</td><td align="center">1.3</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td><td align="center">1.5</td></tr></tbody></table><table-wrap-foot><p>Dose values are given in GBq.</p><p>
<italic>BSA</italic>&#x02009;=&#x02009;Body surface area.</p></table-wrap-foot></table-wrap><p>The dose of bevacizumab administered in the study will be according to standard institutional protocols (usually 5&#x02013;10&#x000a0;mg/kg) and should be infused on the first day of each chemotherapy cycle, commencing with cycle 1 in the control arm. In the intervention arm, bevacizumab should be withheld until at least cycle 4 to mitigate the risk of additive toxicity should the non-targeted delivery of SIR-Spheres to the gastrointestinal tract occur. If non-targeted delivery is suspected, then gastroduodenoscopy will be undertaken before the initiation of bevacizumab therapy. If gastroduodenoscopy reveals an ulcer with biopsy-proven microspheres present, bevacizumab will be withheld until resolution of the ulcer.</p><p>In both arms, if following treatment response the patient is deemed a candidate for surgical resection, and the patient undergoes surgical resection and/or complete ablation of their primary and metastatic cancer, adjuvant cycles of protocol mFOLFOX6&#x02009;&#x000b1;&#x02009;bevacizumab will be continued for a minimum of 12&#x000a0;cycles (including pre-operative cycles).</p></sec><sec id="Sec7"><title>Outcome measures</title><p>The primary outcome measure of the SIRFLOX study is a comparison between treatment arms of PFS. Secondary outcomes will include: PFS in the liver; OS; tumour response rate (liver and any site); health-related quality of life (HRQoL); toxicity and safety; and liver resection rate.</p></sec><sec id="Sec8"><title>Outcome definitions</title><p>OS is defined as the time from the date of randomisation to death from any cause. Patients lost to follow-up, withdrawn, or alive at study completion will be censored at the last date that the patient is known to be alive. PFS is defined as the time from the date of randomisation to confirmation of disease progression at any site (RECIST version 1.0 guidelines [<xref ref-type="bibr" rid="CR25">25</xref>]) or death from any cause if this occurs before disease progression is documented. Patients who change treatment for reasons other than progression (other than patients who are deemed suitable for surgery) will be censored at change of treatment. PFS and tumour response rate will be determined from serial CT scans using RECIST version 1.0 criteria. Centralised assessment of CT scans and tumour response will be conducted by two independent, board-certified radiologists. Cases of disagreement in the judgment of PFS by the two readers will be adjudicated by a medical oncologist based on both radiological and clinical criteria. The PFS based upon the centralised review constitutes the primary endpoint.</p><p>HRQoL will be measured using two questionnaires, the EQ-5D and the EORTC QLQ-30. Adverse events (AEs) and Serious Adverse Events (SAEs) will be collected in accordance with ISO14155 and the International Conference on Harmonisation (ICH) guidelines, and will be rated according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0 and the relationship to protocol therapy will be rated as none, unlikely, possible or probable.</p><p>After 360 patients (80% of the intended sample size) have completed 15&#x000a0;months of follow-up, at least 300 progressions are expected. The actual pooled event rate will be assessed at this time by an independent data monitoring and safety monitoring committee (IDMC) to determine if the study should continue as planned.</p></sec><sec id="Sec9"><title>Assessment procedures and timing</title><p>All patients will be assessed by the criteria summarised in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Additional non-study assessments are permitted at the discretion of the treating investigator.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>SIRFLOX study assessment schedule</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Screening</th><th colspan="3">During chemotherapy</th><th>Post-progression follow-up</th></tr><tr><th>Evaluation/examination</th><th>(&#x02264;28 d before randomisation)</th><th>Day 1</th><th>Day 3 or 4 of cycle 1</th><th>Every 2&#x000a0;weeks &#x000b1;1 week
<sup>a</sup>
</th><th>(every 12&#x000a0;weeks)</th></tr></thead><tbody><tr><td>Informed consent</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Demographics</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Medical history</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Concomitant illnesses</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Concurrent medications</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center"/></tr><tr><td>Clinical assessment and physical examination</td><td align="center">X</td><td align="center">X</td><td align="center"/><td align="center">X</td><td align="center"/></tr><tr><td>Performance status</td><td align="center">X</td><td align="center">X</td><td align="center"/><td align="center">X</td><td align="center"/></tr><tr><td>Haematology<sup>b</sup>
</td><td align="center">X</td><td align="center">X</td><td align="center"/><td align="center">X</td><td align="center"/></tr><tr><td>Biochemistry<sup>c</sup>
</td><td align="center">X</td><td align="center">X</td><td align="center"/><td align="center">X</td><td align="center"/></tr><tr><td>Pregnancy test</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Serum CEA</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center">X<sup>d</sup>
</td><td align="center"/></tr><tr><td>CT of chest/abdomen/pelvis</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center">X<sup>e</sup>
</td><td align="center">X</td></tr><tr><td>Assessment for resection</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center">X<sup>e</sup>
</td><td align="center"/></tr><tr><td>Hepatic angiogram<sup>f</sup>
</td><td align="center"/><td align="center">X<sup>g</sup>
</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>
<sup>99m</sup>Tc-MAA lung shunt study<sup>f</sup>
</td><td align="center"/><td align="center">X<sup>g</sup>
</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Adverse events</td><td align="center" colspan="5">From consent until 28&#x000a0;days after the last dose of protocol chemotherapy</td></tr><tr><td>EQ-5D HRQoL</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center">X<sup>h</sup>
</td><td align="center"/></tr><tr><td>EORTC QLQ-C30 HRQoL</td><td align="center">X</td><td align="center"/><td align="center"/><td align="center">X<sup>i</sup>
</td><td align="center"/></tr><tr><td>Ongoing review of treatment and survival</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">X</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Before each cycle of chemotherapy unless otherwise stated.</p><p>
<sup>b</sup>Measurement of haemoglobin, platelets, white blood cells, absolute neutrophils and absolute lymphocytes.</p><p>
<sup>c</sup>Urea, creatinine, liver enzymes, alkaline phosphatase, bilirubin and albumin.</p><p>
<sup>d</sup>Every 4&#x000a0;weeks.</p><p>
<sup>e</sup>Every 8&#x000a0;weeks.</p><p>
<sup>f</sup>Intervention arm only.</p><p>
<sup>g</sup>7&#x000a0;days &#x000b1;4&#x000a0;days before SIRT.</p><p>
<sup>h</sup>EQ-5D questionnaire completed at 3, 6, 12, 24, 36&#x000a0;months, and annually thereafter.</p><p>
<sup>i</sup>4 weeks and 12&#x000a0;months after starting treatment.</p><p>
<italic>CEA</italic>&#x02009;=&#x02009;Carcinoembryonic antigen; <italic>CT</italic>&#x02009;=&#x02009;Computed tomography.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Sample size calculation and statistical considerations</title><p>The potential benefit of adding bevacizumab to FOLFOX is approximately a 4-week increase in median PFS [<xref ref-type="bibr" rid="CR17">17</xref>]. Based on previously reported data, a median PFS time of 8.5&#x000a0;months may be expected with FOLFOX in patients with liver-only or liver-dominant mCRC (i.e., in the control arm); and therefore, with the addition of bevacizumab, median PFS time could be estimated at 9.4&#x000a0;months. Based on previously reported data of SIRT plus hepatic artery chemotherapy (median PFS of 16&#x000a0;months [<xref ref-type="bibr" rid="CR24">24</xref>]) and SIRT plus first-line 5-FU/LV chemotherapy (median PFS of 18.6&#x000a0;months [<xref ref-type="bibr" rid="CR22">22</xref>]), a conservative estimation of median PFS in the intervention arm would be 15&#x000a0;months for patients with liver-only metastases and 10&#x000a0;months for patients with liver-dominant metastatic disease. Using these data and assuming a liver-dominant:liver-only ratio of 40:60, a sample size of at least 450 patients for the SIRFLOX study was estimated to detect an increase in the median PFS from 9.4&#x000a0;months to 12.5&#x000a0;months with 80% power and 95% confidence.</p><p>Primary and secondary endpoints will be analysed according to the intention-to-treat (ITT) principle. Response rates will be compared between treatment arms using a test of proportions, and time to event endpoints will be compared using the log-rank test. The primary endpoint will be assessed in the ITT population, and additional analyses will also assess endpoints in sub-groups: no bevacizumab versus with bevacizumab; presence versus absence of extra-hepatic metastases; and tumour involvement of the liver &#x02264;25% versus &#x0003e;25%. Exploratory analyses will be performed adjusting for prognostic factors in a multivariate analysis framework.</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>The SIRFLOX study will assess the efficacy and safety of SIRT in combination with FOLFOX-based systemic chemotherapy as first-line treatment of patients with inoperable liver-only or liver-predominant mCRC. To date, efficacy and safety data for this combination are available in a limited number of patients [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], and for the use of SIRT in chemotherapy-refractory mCRC [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. Although SIRT has been delivered to more than 35,000 patients in over 600 specialist centres worldwide since 2000, such large-scale studies of this treatment have not been feasible before. However, skilled centres are now numerous enough worldwide to enable recruitment of a large pool of patients for these studies.</p><p>Some aspects of the treatment arms of the SIRFLOX study are worth further discussion. The prescribed activity of SIR-Spheres was determined by the results of the previous dose-escalation study of SIR-Spheres&#x02009;+&#x02009;FOLFOX4 [<xref ref-type="bibr" rid="CR23">23</xref>]. Furthermore, in patients randomised to receive SIRT in the SIRFLOX study, the dose of oxaliplatin is reduced to 60&#x000a0;mg/m<sup>2</sup> for the first three cycles of chemotherapy, and in subsequent cycles is increased to the standard dose of 85&#x000a0;mg/m<sup>2</sup>. One safety concern is that the oxaliplatin in the chemotherapy regimen is a radio-sensitising agent, which when used in combination with external-beam radiation therapy results in hepatotoxicity at doses &#x0003e;60&#x000a0;mg/m<sup>2</sup> [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. The earlier dose-escalation study of SIR-Spheres&#x02009;+&#x02009;FOLFOX4 also concluded that oxaliplatin at doses &#x0003e;60&#x000a0;mg/m<sup>2</sup> in the first three cycles of chemotherapy could increase the occurrence of grade 3 and 4 neutropenia [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>mFOLFOX6 chemotherapy has become widely adopted for the treatment of mCRC, largely because it does not require the day-2 bolus injections of 5-FU that is part of FOLFOX4 and is therefore more convenient. Although previous trials have shown that first-line SIR-Spheres plus chemotherapy can significantly increase time-to-progression and survival in patients with mCRC [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], these used chemotherapy regimens that are now outdated in the management of mCRC. This provides the rationale for choosing mFOLFOX6 in the study. mFOLFOX6 includes oxaliplatin doses of 85&#x000a0;mg/m<sup>2</sup> rather than the dose of 100&#x000a0;mg/m<sup>2</sup> used in FOLFOX6 [<xref ref-type="bibr" rid="CR33">33</xref>] &#x02013; thus, this will maximise the time that patients can receive protocol chemotherapy before peripheral neuropathy becomes an issue (which necessitates the removal of oxaliplatin) [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>Patient stratification in SIRFLOX includes the intention to use bevacizumab. The addition of bevacizumab to chemotherapy regimens may enhance survival times and PFS in patients with mCRC [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], but little is known about the potential added benefits of primary chemotherapy&#x02009;+&#x02009;bevacizumab&#x02009;+&#x02009;SIRT. Data on bevacizumab and the other biological agents such as cetuximab and panitumumab for the treatment of liver-only mCRC are limited and sometimes contradictory [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>], which has made guidance on the optimal first-line treatment strategies difficult and sometimes conflicting [<xref ref-type="bibr" rid="CR42">42</xref>]. Indeed, despite the initial enthusiasm with targeted biological agents and evidence that they can improve 2-year survival, no gains in 5-year survival have been observed with these agents [<xref ref-type="bibr" rid="CR43">43</xref>]. The approach of combining systemic chemotherapy&#x02009;&#x000b1;&#x02009;biologic agents with targeted radiation therapy may provide enhanced benefits in mCRC.</p><p>Another strata that will be assessed in these trials is the absence or presence of extra-hepatic metastases. Although published efficacy data on SIRT and FOLFOX chemotherapy are limited, initial data did indicate considerably longer PFS and OS among patients with liver-only disease [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>In addition to the SIRFLOX study, SIRT in combination with FOLFOX-based systemic chemotherapy as first-line treatment of patients with inoperable liver-only or liver-predominant mCRC is being investigated in the FOXFIRE trial. The studies have almost identical protocols, and FOXFIRE has as a primary endpoint an <italic>a priori</italic> analysis of OS of all patients included in SIRFLOX and FOXFIRE.</p><p>A recent consensus statement on systemic cytotoxic and biological therapies for liver metastases from CRC summarised expert recommendations on the management of patients with non-resectable metastatic tumours [<xref ref-type="bibr" rid="CR44">44</xref>]. In the accompanying editorial [<xref ref-type="bibr" rid="CR45">45</xref>], Clary et al. identified the need to optimise outcomes of systemic treatment in patients with non-resectable liver metastases as a key question to be addressed. The SIRFLOX study and FOXFIRE trial aim to address this issue in a large patient population and may help provide important new evidence on the use of SIRT early in the therapeutic cascade to enhance PFS and/or OS in this patient population. The use of SIRT with yttrium-90 resin microspheres was not specifically addressed in the consensus statement, presumably due to the paucity of data [<xref ref-type="bibr" rid="CR44">44</xref>]. Clary et al. highlighted this omission and concluded, &#x0201c;The optimal use of these modalities is undefined and requires further study&#x0201d; [<xref ref-type="bibr" rid="CR45">45</xref>]. The results from the SIRFLOX study and FOXFIRE trial should further our understanding of SIRT, may help define the optimal use of this treatment modality in mCRC, and may place this treatment option at the forefront of future consensus guidelines.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec12"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2014_5083_MOESM1_ESM.pdf"><caption><p>Additional file 1:
<bold>Participating centres and ethics committees that have approved the SIRFLOX study.</bold> Table of participating centres ethics committees that have approved the SIRFLOX study. (PDF 183 KB)</p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>BSA</term><def><p>Body surface area</p></def></def-item><def-item><term>CRC</term><def><p>Colorectal cancer</p></def></def-item><def-item><term>5-FU</term><def><p>5-Fluorouracil</p></def></def-item><def-item><term>HRQoL</term><def><p>Health-related quality of life</p></def></def-item><def-item><term>ITT</term><def><p>Intention-to-treat</p></def></def-item><def-item><term>LV</term><def><p>Leucovorin</p></def></def-item><def-item><term>OS</term><def><p>Overall survival</p></def></def-item><def-item><term>PFS</term><def><p>Progression-free survival</p></def></def-item><def-item><term>RECIST</term><def><p>Response evaluation criteria in solid tumours</p></def></def-item><def-item><term>SIRT</term><def><p>Selective internal radiation therapy.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>PG has received honoraria from Sirtex for participation in advisory boards and for giving presentations. VG has received compensation for participation in Advisory Committees from Sirtex. MVB has received consultancy fees from Sirtex. DC is CMO/full time employee of Sirtex Medical Limited. KT is a full time employee of Sirtex Medical Limited. GVH has received compensation for participation in Advisory Committees from Sirtex.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>All authors were substantially involved in the conception and design of the SIRFLOX study. All authors were involved in drafting or critically reviewing each draft of the manuscript for important intellectual content, and all authors read and approved the final draft of the manuscript for submission.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank all investigators in the SIRFLOX Study Group, and in particular the Principal Investigators: Pradip Amin (USA), Bruna Angelelli (Italy), Jacques Balosso (France), Alex Beny (Israel), Daniel Bloomgarden (USA), Eveline Boucher (France), Michael Brown (Australia), Harald-Robert Bruch (Germany), James Bui (USA), Matthew Burge (Australia), Giuseppe Cardaci (Australia), James Carlisle (USA), Yi-Jen Chen (USA), Patrick Chevallier (France), Stephen Clarke (Australia), Andrew Coveler (USA), Michel Craninx (Belgium), Thierry Delanoit (Belgium), Am&#x000e9;lie Deleporte (Belgium), Paul Eliadis (Australia), Francis Facchini (USA), Thomas Ferguson (Australia), Michel Ferrante (Belgium), Michael Findlay (New Zealand), Gary Frenette (USA), Jacob Frick (USA), Vinod Ganju (Australia), Michael Garofalo (USA), Karen Geboes (Belgium), Gerald Gehbauer (Germany), Benjamin George (USA), Ravit Geva (Israel), Michael Gordon (USA), Seza Gulac (USA), James Hannigan (USA), Volker Heinemann (Germany), Thomas Helmberger (Germany), Matthew Holtzman (USA), Richard Isaacs (New Zealand), Philip James (Australia), Andreas Kaubisch (USA), Yon-Dschun Ko (Germany), Todd Kooy (USA), Hendrik Kr&#x000f6;ning (Germany), Frank Lammert (Germany), Winston Liauw (Australia), Samy Louafi (France), Marc de Man (Belgium), Jeffrey Margolis (USA), Robert Martin (USA), Gavin Marx (Australia), Marco Matos (Australia), Els Monsaert (Belgium), Veerle Moons (Belgium), Louise Nott (Australia), Arnd Nusch (Germany), Anne O&#x02019;Donnell (New Zealand), Howard Ozer (USA), Siddarth Padia (USA), Nick Pavlakis (Australia), Marc Peeters (Belgium), David Perez (New Zealand), Stefan Pluntke (Germany), Marc Polus (Belgium), Alex Powell (Australia), Timothy Price (Australia), David Ransom (Australia), Christine Rebischung (France), Karsten Ridwelski (Germany), Hanno Riess (Germany), Jorge Ramon Riera (Germany), Jens Ricke (Germany), William Rilling (USA), Bridget Robinson (New Zealand), Javier Rodr&#x000ed;guez (Spain), Tilmann Sauerbruch (Germany), Michael Savin (USA), Klemens Scheidhauer (Germany), Elyse Schneiderman (USA), Grant Seeger (USA), Eva Segelov (Australia), Einat Shaham Schmueli (Israel), Adi Shani (Israel), Jenny Shannon (Australia), Navesh Sharma (USA), Stephen Shibata (USA), Nimit Singhal (Australia), Denis Smith (France), Randall Smith (USA), Salomon Stemmer (Israel), Oliver St&#x000f6;tzer (Germany), Andrew Strickland (Australia), Julien Taieb (France), Klaus Tatsch (Germany), Eric Terrebonne (France), Thomas Tichler (Israel), Ursula Vehling-Kaiser (Germany), Ruth Vera-Garcia (Spain), Thomas Vogl (Germany), Euan Walpole (Australia), Eric Wang (USA), Samuel Whiting (USA), Ido Wolf (Israel).</p><p>This study was sponsored by Sirtex Technology Pty Ltd. The authors would like to acknowledge Bruce Gray for his involvement in the development of the initial protocol. We acknowledge the editorial assistance provided by Martin Gilmour of ESP Bioscience (Crowthorne, UK) funded by Sirtex, during the preparation of this manuscript.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>JP</given-names></name><name><surname>Donaldson</surname><given-names>GA</given-names></name></person-group><article-title>The clinical correlation of an autopsy study of recurrent colorectal cancer</article-title><source>Ann Surg</source><year>1979</year><volume>189</volume><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1097/00000658-197904000-00027</pub-id><pub-id pub-id-type="pmid">443905</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>V</given-names></name><name><surname>Hollands</surname><given-names>M</given-names></name></person-group><article-title>Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis</article-title><source>ISRN Oncol</source><year>2011</year><volume>2011</volume><fpage>763245</fpage><pub-id pub-id-type="pmid">22091431</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name></person-group><article-title>Developing strategies for liver metastases from colorectal cancer</article-title><source>Semin Oncol</source><year>2007</year><volume>34</volume><fpage>S7</fpage><lpage>S11</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2007.01.003</pub-id><pub-id pub-id-type="pmid">17449352</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Fortner</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>RL</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name></person-group><article-title>Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases</article-title><source>Ann Surg</source><year>1999</year><volume>230</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1097/00000658-199909000-00004</pub-id><pub-id pub-id-type="pmid">10493478</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choti</surname><given-names>MA</given-names></name><name><surname>Sitzmann</surname><given-names>JV</given-names></name><name><surname>Tiburi</surname><given-names>MF</given-names></name><name><surname>Sumetchotimetha</surname><given-names>W</given-names></name><name><surname>Rangsin</surname><given-names>R</given-names></name><name><surname>Schulick</surname><given-names>RD</given-names></name><name><surname>Lillemoe</surname><given-names>KD</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Cameron</surname><given-names>JL</given-names></name></person-group><article-title>Trends in long-term survival following liver resection for hepatic colorectal metastases</article-title><source>Ann Surg</source><year>2002</year><volume>235</volume><fpage>759</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1097/00000658-200206000-00002</pub-id><pub-id pub-id-type="pmid">12035031</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stangl</surname><given-names>R</given-names></name><name><surname>Altendorf-Hofmann</surname><given-names>A</given-names></name><name><surname>Charnley</surname><given-names>RM</given-names></name><name><surname>Scheele</surname><given-names>J</given-names></name></person-group><article-title>Factors influencing the natural history of colorectal liver metastases</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>1405</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)92529-1</pub-id><pub-id pub-id-type="pmid">7515134</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothbarth</surname><given-names>J</given-names></name><name><surname>van de Velde</surname><given-names>CJ</given-names></name></person-group><article-title>Treatment of liver metastases of colorectal cancer</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><issue>Suppl 2</issue><fpage>ii144</fpage><lpage>ii149</lpage><pub-id pub-id-type="pmid">15958446</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berber</surname><given-names>E</given-names></name><name><surname>Pelley</surname><given-names>R</given-names></name><name><surname>Siperstein</surname><given-names>AE</given-names></name></person-group><article-title>Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>1358</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.12.039</pub-id><pub-id pub-id-type="pmid">15684312</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarra</surname><given-names>G</given-names></name><name><surname>Ayav</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>JC</given-names></name><name><surname>Jensen</surname><given-names>SL</given-names></name><name><surname>Smadga</surname><given-names>C</given-names></name><name><surname>Nicholls</surname><given-names>JP</given-names></name><name><surname>Habib</surname><given-names>NA</given-names></name><name><surname>Jiao</surname><given-names>LR</given-names></name></person-group><article-title>Short- and-long term results of intraoperative radiofrequency ablation of liver metastases</article-title><source>Int J Colorectal Dis</source><year>2005</year><volume>20</volume><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1007/s00384-005-0743-4</pub-id><pub-id pub-id-type="pmid">15864606</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Kohne</surname><given-names>CH</given-names></name><name><surname>Pozzo</surname><given-names>C</given-names></name><name><surname>Poston</surname><given-names>G</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><collab>European Colorectal Metastases Treatment G</collab></person-group><article-title>Towards a pan-European consensus on the treatment of patients with colorectal liver metastases</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><fpage>2212</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.04.012</pub-id><pub-id pub-id-type="pmid">16904315</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>MC</given-names></name><name><surname>Pulitano</surname><given-names>C</given-names></name><name><surname>Ribero</surname><given-names>D</given-names></name><name><surname>Strub</surname><given-names>J</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><name><surname>Schulick</surname><given-names>RD</given-names></name><name><surname>Choti</surname><given-names>MA</given-names></name><name><surname>Aldrighetti</surname><given-names>L</given-names></name><name><surname>Capussotti</surname><given-names>L</given-names></name><name><surname>Pawlik</surname><given-names>TM</given-names></name></person-group><article-title>Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients</article-title><source>Ann Surg</source><year>2009</year><volume>250</volume><fpage>440</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">19730175</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piedbois</surname><given-names>P</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Pignon</surname><given-names>J</given-names></name><name><surname>Ryan</surname><given-names>L</given-names></name><name><surname>Hansen</surname><given-names>R</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Weinerman</surname><given-names>B</given-names></name><name><surname>Pater</surname><given-names>J</given-names></name><name><surname>Leichman</surname><given-names>C</given-names></name><name><surname>Macdonald</surname><given-names>J</given-names></name><name><surname>Benedetti</surname><given-names>J</given-names></name><name><surname>Lokich</surname><given-names>J</given-names></name><name><surname>Fryer</surname><given-names>J</given-names></name><name><surname>Brufman</surname><given-names>G</given-names></name><name><surname>Isacson</surname><given-names>R</given-names></name><name><surname>Laplanche</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>E</given-names></name><collab>Meta-analysis Group In Cancer</collab></person-group><article-title>Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">9440757</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1056/NEJM200009283431302</pub-id><pub-id pub-id-type="pmid">11006366</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Morton</surname><given-names>RF</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Ramanathan</surname><given-names>RK</given-names></name><name><surname>Williamson</surname><given-names>SK</given-names></name><name><surname>Findlay</surname><given-names>BP</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Alberts</surname><given-names>SR</given-names></name></person-group><article-title>A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.09.046</pub-id><pub-id pub-id-type="pmid">14665611</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Achille</surname><given-names>E</given-names></name><name><surname>Lledo</surname><given-names>G</given-names></name><name><surname>Flesh</surname><given-names>M</given-names></name><name><surname>Mery-Mignard</surname><given-names>D</given-names></name><name><surname>Quinaux</surname><given-names>E</given-names></name><name><surname>Couteau</surname><given-names>C</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Ganem</surname><given-names>G</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Colin</surname><given-names>P</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.05.113</pub-id><pub-id pub-id-type="pmid">14657227</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurwitz</surname><given-names>H</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name><name><surname>Cartwright</surname><given-names>T</given-names></name><name><surname>Hainsworth</surname><given-names>J</given-names></name><name><surname>Heim</surname><given-names>W</given-names></name><name><surname>Berlin</surname><given-names>J</given-names></name><name><surname>Baron</surname><given-names>A</given-names></name><name><surname>Griffing</surname><given-names>S</given-names></name><name><surname>Holmgren</surname><given-names>E</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Fyfe</surname><given-names>G</given-names></name><name><surname>Rogers</surname><given-names>B</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name><name><surname>Kabbinavar</surname><given-names>F</given-names></name></person-group><article-title>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2335</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032691</pub-id><pub-id pub-id-type="pmid">15175435</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Koski</surname><given-names>S</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Couture</surname><given-names>F</given-names></name><name><surname>Sirzen</surname><given-names>F</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name></person-group><article-title>Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2013</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9930</pub-id><pub-id pub-id-type="pmid">18421054</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Alberts</surname><given-names>S</given-names></name><name><surname>Raab</surname><given-names>HR</given-names></name><name><surname>Kohne</surname><given-names>CH</given-names></name></person-group><article-title>Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>1311</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi246</pub-id><pub-id pub-id-type="pmid">15870084</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Delvart</surname><given-names>V</given-names></name><name><surname>Pascal</surname><given-names>G</given-names></name><name><surname>Valeanu</surname><given-names>A</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Azoulay</surname><given-names>D</given-names></name><name><surname>Giacchetti</surname><given-names>S</given-names></name><name><surname>Paule</surname><given-names>B</given-names></name><name><surname>Kunstlinger</surname><given-names>F</given-names></name><name><surname>Ghemard</surname><given-names>O</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name></person-group><article-title>Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><fpage>644</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000145964.08365.01</pub-id><pub-id pub-id-type="pmid">15383792</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>Colorectal cancer: integrating oxaliplatin</article-title><source>Curr Treat Options Oncol</source><year>2003</year><volume>4</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1007/s11864-003-0041-8</pub-id><pub-id pub-id-type="pmid">12941200</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giantonio</surname><given-names>BJ</given-names></name><name><surname>Catalano</surname><given-names>PJ</given-names></name><name><surname>Meropol</surname><given-names>NJ</given-names></name><name><surname>O&#x02019;Dwyer</surname><given-names>PJ</given-names></name><name><surname>Mitchell</surname><given-names>EP</given-names></name><name><surname>Alberts</surname><given-names>SR</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name><name><surname>Benson</surname><given-names>AB</given-names><suffix>3rd</suffix></name><collab>Eastern Cooperative Oncology Group Study E</collab></person-group><article-title>Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1539</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.6305</pub-id><pub-id pub-id-type="pmid">17442997</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Hazel</surname><given-names>G</given-names></name><name><surname>Blackwell</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Moroz</surname><given-names>P</given-names></name><name><surname>Bower</surname><given-names>G</given-names></name><name><surname>Cardaci</surname><given-names>G</given-names></name><name><surname>Gray</surname><given-names>B</given-names></name></person-group><article-title>Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer</article-title><source>J Surg Oncol</source><year>2004</year><volume>88</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/jso.20141</pub-id><pub-id pub-id-type="pmid">15499601</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>RA</given-names></name><name><surname>Van Hazel</surname><given-names>GA</given-names></name><name><surname>Morgan</surname><given-names>B</given-names></name><name><surname>Berry</surname><given-names>DP</given-names></name><name><surname>Blanshard</surname><given-names>K</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Bower</surname><given-names>G</given-names></name><name><surname>Shannon</surname><given-names>JA</given-names></name><name><surname>Gibbs</surname><given-names>P</given-names></name><name><surname>Steward</surname><given-names>WP</given-names></name></person-group><article-title>Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1099</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.7916</pub-id><pub-id pub-id-type="pmid">17369573</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>B</given-names></name><name><surname>Van Hazel</surname><given-names>G</given-names></name><name><surname>Hope</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>M</given-names></name><name><surname>Moroz</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Gebski</surname><given-names>V</given-names></name></person-group><article-title>Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>1711</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1023/A:1013569329846</pub-id><pub-id pub-id-type="pmid">11843249</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>RS</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Gwyther</surname><given-names>SG</given-names></name></person-group><article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1093/jnci/92.3.205</pub-id><pub-id pub-id-type="pmid">10655437</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosmider</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>TH</given-names></name><name><surname>Yip</surname><given-names>D</given-names></name><name><surname>Dowling</surname><given-names>R</given-names></name><name><surname>Lichtenstein</surname><given-names>M</given-names></name><name><surname>Gibbs</surname><given-names>P</given-names></name></person-group><article-title>Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer</article-title><source>J Vasc Interv Radiol</source><year>2011</year><volume>22</volume><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/j.jvir.2011.02.023</pub-id><pub-id pub-id-type="pmid">21515072</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendlisz</surname><given-names>A</given-names></name><name><surname>Van den Eynde</surname><given-names>M</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Maleux</surname><given-names>G</given-names></name><name><surname>Lambert</surname><given-names>B</given-names></name><name><surname>Vannoote</surname><given-names>J</given-names></name><name><surname>De Keukeleire</surname><given-names>K</given-names></name><name><surname>Verslype</surname><given-names>C</given-names></name><name><surname>Defreyne</surname><given-names>L</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Delatte</surname><given-names>P</given-names></name><name><surname>Delaunoit</surname><given-names>T</given-names></name><name><surname>Personeni</surname><given-names>N</given-names></name><name><surname>Paesmans</surname><given-names>M</given-names></name><name><surname>Van Laethem</surname><given-names>JL</given-names></name><name><surname>Flamen</surname><given-names>P</given-names></name></person-group><article-title>Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>3687</fpage><lpage>3694</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.5643</pub-id><pub-id pub-id-type="pmid">20567019</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bester</surname><given-names>L</given-names></name><name><surname>Meteling</surname><given-names>B</given-names></name><name><surname>Pocock</surname><given-names>N</given-names></name><name><surname>Pavlakis</surname><given-names>N</given-names></name><name><surname>Chua</surname><given-names>TC</given-names></name><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name></person-group><article-title>Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients</article-title><source>J Vasc Interv Radiol</source><year>2012</year><volume>23</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.jvir.2011.09.028</pub-id><pub-id pub-id-type="pmid">22079516</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidensticker</surname><given-names>R</given-names></name><name><surname>Denecke</surname><given-names>T</given-names></name><name><surname>Kraus</surname><given-names>P</given-names></name><name><surname>Seidensticker</surname><given-names>M</given-names></name><name><surname>Mohnike</surname><given-names>K</given-names></name><name><surname>Fahlke</surname><given-names>J</given-names></name><name><surname>Kettner</surname><given-names>E</given-names></name><name><surname>Hildebrandt</surname><given-names>B</given-names></name><name><surname>Dudeck</surname><given-names>O</given-names></name><name><surname>Pech</surname><given-names>M</given-names></name><name><surname>Amthauer</surname><given-names>H</given-names></name><name><surname>Ricke</surname><given-names>J</given-names></name></person-group><article-title>Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases</article-title><source>Cardiovasc Intervent Radiol</source><year>2012</year><volume>35</volume><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1007/s00270-011-0234-7</pub-id><pub-id pub-id-type="pmid">21800231</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khushalani</surname><given-names>NI</given-names></name><name><surname>Leichman</surname><given-names>CG</given-names></name><name><surname>Proulx</surname><given-names>G</given-names></name><name><surname>Nava</surname><given-names>H</given-names></name><name><surname>Bodnar</surname><given-names>L</given-names></name><name><surname>Klippenstein</surname><given-names>D</given-names></name><name><surname>Litwin</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Nava</surname><given-names>E</given-names></name><name><surname>Pendyala</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Greco</surname><given-names>W</given-names></name><name><surname>Berdzik</surname><given-names>J</given-names></name><name><surname>Douglass</surname><given-names>H</given-names></name><name><surname>Leichman</surname><given-names>L</given-names></name></person-group><article-title>Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2844</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.12.032</pub-id><pub-id pub-id-type="pmid">12065561</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freyer</surname><given-names>G</given-names></name><name><surname>Bossard</surname><given-names>N</given-names></name><name><surname>Romestaing</surname><given-names>P</given-names></name><name><surname>Mornex</surname><given-names>F</given-names></name><name><surname>Chapet</surname><given-names>O</given-names></name><name><surname>Trillet-Lenoir</surname><given-names>V</given-names></name><name><surname>Gerard</surname><given-names>JP</given-names></name></person-group><article-title>Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97&#x02013;03 phase I trial</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>2433</fpage><lpage>2438</lpage><pub-id pub-id-type="pmid">11331322</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschele</surname><given-names>C</given-names></name><name><surname>Friso</surname><given-names>ML</given-names></name><name><surname>Pucciarelli</surname><given-names>S</given-names></name><name><surname>Lonardi</surname><given-names>S</given-names></name><name><surname>Sartor</surname><given-names>L</given-names></name><name><surname>Fabris</surname><given-names>G</given-names></name><name><surname>Urso</surname><given-names>ED</given-names></name><name><surname>Del Bianco</surname><given-names>P</given-names></name><name><surname>Sotti</surname><given-names>G</given-names></name><name><surname>Lise</surname><given-names>M</given-names></name><name><surname>Monfardini</surname><given-names>S</given-names></name></person-group><article-title>A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi212</pub-id><pub-id pub-id-type="pmid">15894548</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheeseman</surname><given-names>SL</given-names></name><name><surname>Joel</surname><given-names>SP</given-names></name><name><surname>Chester</surname><given-names>JD</given-names></name><name><surname>Wilson</surname><given-names>G</given-names></name><name><surname>Dent</surname><given-names>JT</given-names></name><name><surname>Richards</surname><given-names>FJ</given-names></name><name><surname>Seymour</surname><given-names>MT</given-names></name></person-group><article-title>A &#x02018;modified de Gramont&#x02019; regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer</article-title><source>Br J Cancer</source><year>2002</year><volume>87</volume><fpage>393</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600467</pub-id><pub-id pub-id-type="pmid">12177775</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cersosimo</surname><given-names>RJ</given-names></name></person-group><article-title>Oxaliplatin-associated neuropathy: a review</article-title><source>Ann Pharmacother</source><year>2005</year><volume>39</volume><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1345/aph.1E319</pub-id><pub-id pub-id-type="pmid">15590869</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>Kretzschmar</surname><given-names>A</given-names></name><name><surname>Michael</surname><given-names>M</given-names></name><name><surname>DiBartolomeo</surname><given-names>M</given-names></name><name><surname>Mazier</surname><given-names>MA</given-names></name><name><surname>Canon</surname><given-names>JL</given-names></name><name><surname>Georgoulias</surname><given-names>V</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Bridgewater</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><collab>BEAT investigators</collab></person-group><article-title>Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><fpage>1842</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp233</pub-id><pub-id pub-id-type="pmid">19406901</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasti</surname><given-names>G</given-names></name><name><surname>Ottaiano</surname><given-names>A</given-names></name><name><surname>Berretta</surname><given-names>M</given-names></name><name><surname>Delrio</surname><given-names>P</given-names></name><name><surname>Izzo</surname><given-names>F</given-names></name><name><surname>Cassata</surname><given-names>A</given-names></name><name><surname>Romano</surname><given-names>C</given-names></name><name><surname>Facchini</surname><given-names>G</given-names></name><name><surname>Scala</surname><given-names>D</given-names></name><name><surname>Mastro</surname><given-names>A</given-names></name><name><surname>Romano</surname><given-names>G</given-names></name><name><surname>Perri</surname><given-names>F</given-names></name><name><surname>Iaffaioli</surname><given-names>RV</given-names></name></person-group><article-title>Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials</article-title><source>Cancer Chemother Pharmacol</source><year>2010</year><volume>66</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1007/s00280-010-1297-x</pub-id><pub-id pub-id-type="pmid">20333385</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Kohne</surname><given-names>CH</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Nowacki</surname><given-names>MP</given-names></name><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Shchepotin</surname><given-names>I</given-names></name><name><surname>Maurel</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Tejpar</surname><given-names>S</given-names></name><name><surname>Schlichting</surname><given-names>M</given-names></name><name><surname>Zubel</surname><given-names>A</given-names></name><name><surname>Celik</surname><given-names>I</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Ciardiello</surname><given-names>F</given-names></name></person-group><article-title>Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>2011</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.33.5091</pub-id><pub-id pub-id-type="pmid">21502544</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Makhson</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Aparicio</surname><given-names>J</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Donea</surname><given-names>S</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Schuch</surname><given-names>G</given-names></name><name><surname>Stroh</surname><given-names>C</given-names></name><name><surname>Loos</surname><given-names>AH</given-names></name><name><surname>Zubel</surname><given-names>A</given-names></name><name><surname>Koralewski</surname><given-names>P</given-names></name></person-group><article-title>Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>663</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.20.8397</pub-id><pub-id pub-id-type="pmid">19114683</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maughan</surname><given-names>TS</given-names></name><name><surname>Adams</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>CG</given-names></name><name><surname>Meade</surname><given-names>AM</given-names></name><name><surname>Seymour</surname><given-names>MT</given-names></name><name><surname>Wilson</surname><given-names>RH</given-names></name><name><surname>Idziaszczyk</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Kenny</surname><given-names>SL</given-names></name><name><surname>Kay</surname><given-names>E</given-names></name><name><surname>Mitchell</surname><given-names>JK</given-names></name><name><surname>Madi</surname><given-names>A</given-names></name><name><surname>Jasani</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>MD</given-names></name><name><surname>Bridgewater</surname><given-names>J</given-names></name><name><surname>Kennedy</surname><given-names>MJ</given-names></name><name><surname>Claes</surname><given-names>B</given-names></name><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Cheadle</surname><given-names>JP</given-names></name><collab>MRC COIN Trial Investigators</collab></person-group><article-title>Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial</article-title><source>Lancet</source><year>2011</year><volume>377</volume><fpage>2103</fpage><lpage>2114</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60613-2</pub-id><pub-id pub-id-type="pmid">21641636</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tveit</surname><given-names>KM</given-names></name><name><surname>Guren</surname><given-names>T</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Pfeiffer</surname><given-names>P</given-names></name><name><surname>Sorbye</surname><given-names>H</given-names></name><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>Sigurdsson</surname><given-names>F</given-names></name><name><surname>Kure</surname><given-names>E</given-names></name><name><surname>Ikdahl</surname><given-names>T</given-names></name><name><surname>Skovlund</surname><given-names>E</given-names></name><name><surname>Fokstuen</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>F</given-names></name><name><surname>Hofsli</surname><given-names>E</given-names></name><name><surname>Birkemeyer</surname><given-names>E</given-names></name><name><surname>Johnsson</surname><given-names>A</given-names></name><name><surname>Starkhammar</surname><given-names>H</given-names></name><name><surname>Yilmaz</surname><given-names>MK</given-names></name><name><surname>Keldsen</surname></name><name><surname>Erdal</surname><given-names>AB</given-names></name><name><surname>Dajani</surname><given-names>O</given-names></name><name><surname>Dahl</surname><given-names>O</given-names></name><name><surname>Christoffersen</surname><given-names>T'</given-names></name></person-group><article-title>Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1755</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.38.0915</pub-id><pub-id pub-id-type="pmid">22473155</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>SW</given-names></name><name><surname>Huang</surname><given-names>YY</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>ZM</given-names></name><name><surname>Zhang</surname><given-names>YD</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Xie</surname><given-names>DR</given-names></name></person-group><article-title>No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e50925</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0050925</pub-id><pub-id pub-id-type="pmid">23226426</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>T</given-names></name></person-group><article-title>Biologic therapies in the metastatic colorectal cancer treatment continuum&#x02013;applying current evidence to clinical practice</article-title><source>Cancer Treat Rev</source><year>2012</year><volume>38</volume><fpage>397</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2011.08.002</pub-id><pub-id pub-id-type="pmid">21899955</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>E</given-names></name></person-group><article-title>An update on the current and emerging targeted agents in metastatic colorectal cancer</article-title><source>Clin Colorectal Cancer</source><year>2012</year><volume>11</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.clcc.2011.05.005</pub-id><pub-id pub-id-type="pmid">21752724</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>RE</given-names></name><name><surname>Berlin</surname><given-names>JD</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Choti</surname><given-names>MA</given-names></name></person-group><article-title>Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement</article-title><source>HPB</source><year>2013</year><volume>15</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/j.1477-2574.2012.00558.x</pub-id><pub-id pub-id-type="pmid">23297721</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clary</surname><given-names>BM</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Marsh</surname><given-names>RD</given-names></name></person-group><article-title>Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement</article-title><source>HPB</source><year>2013</year><volume>15</volume><fpage>116</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1111/j.1477-2574.2012.00598.x</pub-id><pub-id pub-id-type="pmid">23297722</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR46"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/897/prepub">http://www.biomedcentral.com/1471-2407/14/897/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>